Key result
Transcatheter transapical mitral valve-in-valve implantation for failed mitral bioprostheses showed similar in-hospital mortality (4.7% vs 7.5%; OR 2.46, P=0.512) compared to minimally invasive surgery.
Why the study?
Does transcatheter transapical mitral valve-in-valve implantation improve early outcomes and survival compared to minimally invasive surgery in patients with failed mitral bioprostheses?
Cohort (n=61)
No
Does transcatheter transapical mitral valve-in-valve implantation improve early outcomes and survival compared to minimally invasive surgery in patients with failed mitral bioprostheses?
Odds Ratio: 2.46
Absolute Event Rate: 4.7% vs 7.5%
p-value: p=0.512
Transapical transcatheter mitral valve-in-valve implantation is a safe alternative to minimally invasive surgery for failed mitral bioprostheses, offering comparable survival and shorter hospital stays despite a higher incidence of mild paravalvular leak.
No takes yet. Share an insight, caveat, or question.
May support transapical TMViV in high-risk patients; leaves open need for randomized confirmation of outcomes.
Murzi et al. (2017) conducted a cohort in Failed mitral bioprostheses (n=61). Transcatheter transapical mitral valve-in-valve (M-VIV) implantation vs. Minimally invasive mitral valve replacement through a right anterior minithoracotomy (MIMVR) was evaluated on In-hospital mortality (OR 2.46, p=0.512). Transcatheter transapical mitral valve-in-valve implantation for failed mitral bioprostheses showed similar in-hospital mortality (4.7% vs 7.5%; OR 2.46, P=0.512) compared to minimally invasive surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: